# A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults

> **NCT06101173** · PHASE1 · COMPLETED · sponsor: **CanSino Biologics Inc.** · enrollment: 72 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)
- **BIOLOGICAL:** Inactivated poliomyelitis vaccine (IPOL)
- **BIOLOGICAL:** VLP-Polio
- **BIOLOGICAL:** IPOL
- **BIOLOGICAL:** VLP-Polio
- **BIOLOGICAL:** IPOL

## Key facts

- **NCT ID:** NCT06101173
- **Lead sponsor:** CanSino Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-15
- **Primary completion:** 2024-03-15
- **Final completion:** 2024-09-11
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06101173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06101173, "A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06101173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*